EP0988295A4 - Durch einen heterozyklischen rest substituierte piperidine und ihre anwendung - Google Patents

Durch einen heterozyklischen rest substituierte piperidine und ihre anwendung

Info

Publication number
EP0988295A4
EP0988295A4 EP98931350A EP98931350A EP0988295A4 EP 0988295 A4 EP0988295 A4 EP 0988295A4 EP 98931350 A EP98931350 A EP 98931350A EP 98931350 A EP98931350 A EP 98931350A EP 0988295 A4 EP0988295 A4 EP 0988295A4
Authority
EP
European Patent Office
Prior art keywords
heterocyclic substituted
substituted piperidines
piperidines
heterocyclic
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98931350A
Other languages
English (en)
French (fr)
Other versions
EP0988295A1 (de
Inventor
Bharat Lagu
T G Murali Dhar
Dhanapalan Nagarathnam
Yoon T Jeon
Mohammad R Marzabadi
Wai C Wong
Charles Gluchowski
Dake Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundbeck Research USA Inc
Original Assignee
Synaptic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaptic Pharmaceutical Corp filed Critical Synaptic Pharmaceutical Corp
Publication of EP0988295A1 publication Critical patent/EP0988295A1/de
Publication of EP0988295A4 publication Critical patent/EP0988295A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP98931350A 1997-06-18 1998-06-17 Durch einen heterozyklischen rest substituierte piperidine und ihre anwendung Withdrawn EP0988295A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87784697A 1997-06-18 1997-06-18
US877846 1997-06-18
PCT/US1998/012668 WO1998057940A1 (en) 1997-06-18 1998-06-17 Heterocyclic substituted piperidines and uses thereof

Publications (2)

Publication Number Publication Date
EP0988295A1 EP0988295A1 (de) 2000-03-29
EP0988295A4 true EP0988295A4 (de) 2003-08-13

Family

ID=25370847

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98931350A Withdrawn EP0988295A4 (de) 1997-06-18 1998-06-17 Durch einen heterozyklischen rest substituierte piperidine und ihre anwendung

Country Status (5)

Country Link
EP (1) EP0988295A4 (de)
JP (1) JP2002505683A (de)
AU (1) AU740064B2 (de)
CA (1) CA2294549A1 (de)
WO (1) WO1998057940A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
US6046331A (en) * 1998-12-17 2000-04-04 Synaptic Pharmaceutical Corporation Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
GB2344821A (en) 1998-12-17 2000-06-21 Merck & Co Inc Crystalline pharmaceutically acceptable salt of an oxazolidinone derivative
US6372911B1 (en) * 1999-02-09 2002-04-16 Merck & Co., Inc. Process for preparing β-hydroxycarbamates and their conversion to oxazolidinones
US6645968B2 (en) 1999-08-03 2003-11-11 Abbott Laboratories Potassium channel openers
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
CA2678577A1 (en) 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
US8440658B2 (en) 2007-12-11 2013-05-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2010010157A2 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
NZ590495A (en) 2008-07-25 2012-10-26 Vitae Pharmaceuticals Inc Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5679997B2 (ja) 2009-02-04 2015-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
EP2448928B1 (de) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. CYCLISCHE 11ß-HYDROXYSTEROID-DEHYDROGENASE-1-HEMMER
WO2011159760A1 (en) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
WO2012059416A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
US9598387B2 (en) * 2012-10-11 2017-03-21 Southern Research Institute Urea and amide derivatives of aminoalkylpiperazines and use thereof
SG11202105250TA (en) * 2018-11-20 2021-06-29 Sironax Ltd Cyclic Ureas
CN116003380B (zh) * 2023-01-31 2024-07-05 天津大学 指纹识别探针、显影剂和介质表面潜指纹荧光成像方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014846A1 (en) * 1994-11-16 1996-05-23 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
WO1997017969A1 (en) * 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3334098A (en) * 1964-05-07 1967-08-01 American Cyanamid Co 1-monocarbocyclic aryl-3-amino-alkanoyl-2-imidazolidinones
CH613205A5 (de) * 1975-06-06 1979-09-14 Hoffmann La Roche
US4377578A (en) * 1976-12-21 1983-03-22 Janssen Pharmaceutica, N.V. Piperazine derivatives
US4410540A (en) * 1981-11-04 1983-10-18 Merrell Dow Pharmaceuticals Inc. Cardiotonic 4-aroylimidazolidin-2-ones
JPH0713017B2 (ja) * 1986-06-18 1995-02-15 日本ケミファ株式会社 脳細胞保護作用を有する医薬組成物
JPH0755937B2 (ja) * 1986-07-29 1995-06-14 日本曹達株式会社 オキサ（チア）ゾリジン誘導体その製造方法及び殺ダニ剤
US5202345A (en) * 1987-08-19 1993-04-13 Shionogi & Co., Ltd. Carbamoylpyrrolidone derivatives and drugs for senile dementia
FR2698359B1 (fr) * 1992-11-25 1995-10-27 Rhone Poulenc Agrochimie Derives de 2-alkoxy 2-imidazoline-5-ones fongicides.
JPH09504272A (ja) * 1993-09-15 1997-04-28 メルク シヤープ エンド ドーム リミテツド ドーパミンアンタゴニストとしてのイミダゾロン及びオキサゾロン誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014846A1 (en) * 1994-11-16 1996-05-23 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
WO1997017969A1 (en) * 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9857940A1 *

Also Published As

Publication number Publication date
EP0988295A1 (de) 2000-03-29
AU8149898A (en) 1999-01-04
JP2002505683A (ja) 2002-02-19
CA2294549A1 (en) 1998-12-23
AU740064B2 (en) 2001-10-25
WO1998057940A1 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
EP0988295A4 (de) Durch einen heterozyklischen rest substituierte piperidine und ihre anwendung
NO20015070L (no) Paroksetin-hydroklorid-anhydrat
DE59811737D1 (de) Elektronischer Schlüssel
IT1284757B1 (it) Chiavistello a battente
ID23889A (id) Turunan-turunan piridina
ATE278695T1 (de) Piperidinderivate
ID21022A (id) Mesin pentekstur gintiran palsu
PT1089996E (pt) Metanossulfonato de paroxetina
FI973651L (fi) Tärkkelysmodifikaatti
DK1131308T3 (da) Piperazin- og piperidinderivater
DE69823139D1 (de) Verblendsturz
FR2779377B1 (fr) Cisaille a double securite
DE69913633D1 (de) Rohrschneider
BR9606815A (pt) Derivados de piperidina 4-(1H-indolil-1-il)-1-substituídos antipsicóticos
NO993460D0 (no) Paroxetine-preparater
ATA109097A (de) Scharnier
FR2758327B1 (fr) Nouvelles arylpiperazines derivees de piperidine
DE69903495D1 (de) Rohrschneider
FR2758849B1 (fr) Charniere de vantail
DK0937458T3 (da) Pyrrolidin- og piperidinderivater
NO992302D0 (no) Piperidin-derivater
FI972239A0 (fi) (Tiofen-2-yyli) piperidiini- tai tetrahydropyridiinikarboksamideja
DE69718201D1 (de) Scharniere
ATA170297A (de) Scharnier
NO20006364D0 (no) Sikkerhetspapir

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07D 417/14 B

Ipc: 7C 07D 413/14 B

Ipc: 7C 07D 401/14 B

Ipc: 7C 07D 401/12 B

Ipc: 7C 07D 265/10 B

Ipc: 7C 07D 263/26 B

Ipc: 7A 61K 31/495 B

Ipc: 7A 61K 31/445 B

Ipc: 7A 61K 31/425 B

Ipc: 7A 61K 31/42 B

Ipc: 7A 61K 31/415 B

Ipc: 7C 07D 413/12 B

Ipc: 7C 07D 411/12 B

Ipc: 7C 07D 403/06 B

Ipc: 7C 07D 277/14 B

Ipc: 7C 07D 263/20 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030626

17P Request for examination filed

Effective date: 20000108

17Q First examination report despatched

Effective date: 20040423

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040904